Purdue Pharma to stop promoting oxycodone to U.S. doctors

Purdue Pharma says it will stop promoting oxycodone (OxyContin) and other opioids to U.S. doctors. The company will continue selling the products, but Purdue's sales force "will no longer be visiting offices to engage in discussions about opioid products," the company says.

Purdue Pharma says it will stop promoting oxycodone (OxyContin) and other opioids to U.S. doctors. The company will continue selling the products, but Purdue's sales force "will no longer be visiting offices to engage in discussions about opioid products," the company says. Doctors and other prescribers who have questions about the drugs will have to contact Purdue's medical affairs department, the company says. Purdue is also cutting its U.S. sales force by more than 50%, to about 200 people. The remaining sales representatives will market non-opioid products. Purdue's halting of its opioid marketing comes as the company faces growing legal scrutiny. More than a dozen states and about 400 cities and counties in the U.S. have sued Purdue or other opioid analgesic makers, accusing them of fueling addiction by misrepresenting the risks of their drugs. In response to the suits, Purdue has said it is "dedicated to being part of the solution" to the opioid crisis.